Literature DB >> 647622

The superselective and the selective one shot methods for treating inoperable cancer of the liver.

Y Kinami, I Miyazaki.   

Abstract

Forty-five patients with inoperable cancer of the liver were treated by the one shot administration of 15-40 mg of Mitomycin C into the hepatic artery, either by the superselective or by the selective one shot method. Fourteen of the patients had primary cancers of the liver, and 31 had metastases to the liver from primary cancers of the stomach, or from the colorectal or other organs. Subjective symptoms improved in 73%, and objective signs improved in 60%. Nineteen patients who received this treatment more than twice showed a mean survival time of 10 months and a 50% survival time of 7.8 months. Therapeutic effects of the selective one shot method were recognized mostly in patients with tumors which were rich in vessels. However, a fairly good result was obtained using the superselective one shot method, even in patients with tumors having relatively few vessels.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 647622     DOI: 10.1002/1097-0142(197805)41:5<1720::aid-cncr2820410511>3.0.co;2-7

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  9 in total

1.  Rationale and indications for perfusion in liver tumors: current data.

Authors:  K Schwemmle; K H Link; B Rieck
Journal:  World J Surg       Date:  1987-08       Impact factor: 3.352

2.  Combination of hepatic arterial infusion and systemic chemotherapy for gastric cancer with synchronous hepatic metastases.

Authors:  T Kano; R Kumashiro; Y Abe; T Notsuka; R Tamada; K Inokuchi
Journal:  Jpn J Surg       Date:  1984-01

3.  Evaluation of conservative therapeutic modalities for hepatocellular carcinoma--analysis of 206 cases.

Authors:  K Ando
Journal:  Gastroenterol Jpn       Date:  1984-10

4.  Magnetic resonance imaging in the diagnosis of tumors of the liver.

Authors:  Y Kinami; H Yokota; M Takata; S Takashima; I Yamamoto
Journal:  Gastroenterol Jpn       Date:  1988-04

5.  Organ distribution and antitumor activity of free and liposomal doxorubicin injected into the hepatic artery.

Authors:  Y Zou; I Horikoshi; T Kasagi; X Gu; R Perez-Soler
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

6.  [Approaches to a selective chemotherapy of hepatocellular carcinoma (author's transl)].

Authors:  J Pausch; A Holstege; D Keppler; W Gerok
Journal:  Klin Wochenschr       Date:  1981-06-15

7.  Phase I study of miriplatin combined with transarterial chemotherapy using CDDP powder in patients with hepatocellular carcinoma.

Authors:  Kenya Kamimura; Takeshi Suda; Yasushi Tamura; Masaaki Takamura; Takeshi Yokoo; Masato Igarashi; Hirokazu Kawai; Satoshi Yamagiwa; Minoru Nomoto; Yutaka Aoyagi
Journal:  BMC Gastroenterol       Date:  2012-09-20       Impact factor: 3.067

8.  A case of advanced hepatocellular carcinoma with portal vein tumor thrombus refractory to epirubicin that showed marked decrease in tumor markers after transcatheter arterial infusion with miriplatin.

Authors:  Hiroki Nishikawa; Tadashi Inuzuka; Haruhiko Takeda; Jun Nakajima; Azusa Sakamoto; Sinichiro Henmi; Tetsurou Ishikawa; Sumio Saito; Ryuichi Kita; Toru Kimura; Yukio Osaki; Yorimitsu Koshikawa
Journal:  Case Rep Oncol       Date:  2010-06-30

9.  Phase II trial of intra-arterial chemotherapy using a novel lipophilic platinum derivative (SM-11355) in patients with hepatocellular carcinoma.

Authors:  Takuji Okusaka; Shuichi Okada; Toshio Nakanishi; Shigetoshi Fujiyama; Yasuhiko Kubo
Journal:  Invest New Drugs       Date:  2004-04       Impact factor: 3.651

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.